@article{7ef9f744e8734dd7bd6faccad319cfc8,
title = "Review of the Diagnosis and Treatment of Periodic Paralysis",
abstract = "Periodic paralyses (PPs) are rare neuromuscular disorders caused by mutations in skeletal muscle sodium, calcium, and potassium channel genes. PPs include hypokalemic paralysis, hyperkalemic paralysis, and Andersen-Tawil syndrome. Common features of PP include autosomal dominant inheritance, onset typically in the first or second decades, episodic attacks of flaccid weakness, which are often triggered by diet or rest after exercise. Diagnosis is based on the characteristic clinic presentation then confirmed by genetic testing. In the absence of an identified genetic mutation, documented low or high potassium levels during attacks or a decrement on long exercise testing support diagnosis. The treatment approach should include both management of acute attacks and prevention of attacks. Treatments include behavioral interventions directed at avoidance of triggers, modification of potassium levels, diuretics, and carbonic anhydrase inhibitors. Muscle Nerve 57: 522–530, 2018.",
keywords = "Andersen-Tawil syndrome, acetazolamide, channelopathies, dichlorphenamide, periodic paralyses, review, treatment",
author = "Statland, {Jeffrey M.} and Bertrand Fontaine and Hanna, {Michael G.} and Johnson, {Nicholas E.} and Kissel, {John T.} and Sansone, {Valeria A.} and Shieh, {Perry B.} and Tawil, {Rabi N.} and Jaya Trivedi and Cannon, {Stephen C.} and Griggs, {Robert C.}",
note = "Funding Information: Funding: N.J. is funded by the NIH, grant #1K23NS091511-01. Funding Information: Conflicts of Interest: J.S. is a consultant for aTyr, Fulcrum, Acceleron, Strongbridge Biopharma, and Novartis. B.F. has received honoraria from Taro Pharmaceuticals. M.H. is a consultant to Novartis. N.J. serves as Deputy Editor for Neurology: Genetics. He has received research support from the Muscular Dystrophy Association, Myotonic Dystrophy Foundation, Valerion Therapeutics, Ionis Pharmaceuticals, and Biogen Idec, and is a consultant for Strongbridge Biopharma. P.S. served on Advisory Boards for Sarepta Therapeutics and Biogen and speakers bureau for Grifols and Biogen. S.C. is a consultant for Strongbridge Biopharma. R.C.G. consults for Medpace, Taro Pharmaceuticals, Marathon Pharmaceuticals, Bamboo Pharmaceuticals, Sarepta Pharmaceuticals, Strongbridge Pharmaceuticals, PTC Therapeutics, and Idera Pharmaceuticals J.T. is on a Speaker{\textquoteright}s Bureau for Sanofi. R.T., V.S., and J.T.K. have nothing to disclose. Publisher Copyright: {\textcopyright} 2017 The Authors Muscle & Nerve Published by Wiley Periodicals, Inc.",
year = "2018",
month = apr,
doi = "10.1002/mus.26009",
language = "English (US)",
volume = "57",
pages = "522--530",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",
}